All treatments
Treatment
BGB-A425, LBL-007, Tislelizumab clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is testing new combinations of medicines to treat a type of head and neck cancer that has come back or spread. Doctors are looking at how well these new treatments shrink the cancer and if they are safe.
For: Head and Neck Squamous Cell CarcinomaFrance · Italy · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
For: Head and Neck Squamous Cell Cancer, Renal Cell Carcinoma, Non-Small Cell Lung CancerFrance · Spain · Poland